Wei Zhentong, Liu Yan, Wang Yishu, Zhang Yandong, Luo Qinghua, Man Xiaxia, Wei Feng, Yu Xiaowei
Department of Oncologic Gynecology, Prenatal Diagnosis Center, The First Hospital of Jilin University, Changchun, 130021, Jilin, People's Republic of China.
Department of Hepatobiliary and Pancreas Surgery, The First Hospital of Jilin University, Changchun, 130021, Jilin, People's Republic of China.
Med Oncol. 2016 Nov;33(11):126. doi: 10.1007/s12032-016-0842-9. Epub 2016 Oct 14.
Ovarian cancer (OVCa) stem cells are associated with tumor growth, metastasis, and recurrence, which are driving forces behind a majority of the OVCa-related mortality. This subpopulation of cancer cells are characterized by uncontrolled proliferation, high invasiveness, and resistance against the current platinum-based therapy. Thus, targeting OVCa cancer stem cells has been focused in recent therapeutic development. Isolation and purification of cancer stem cells are, however, challenging for the lack of sensitive and specific markers. In this study, we demonstrated that miR-551b was upregulated in OVCa stem cells, by using a quantitative PCR array, correlating with the pathological grades of this malignancy. In vitro experiments indicated that miR-551b promoted the proliferation, invasion, and chemoresistance of OVCa cells and cancer stem cells. Further analysis suggested that miR-551b functioned through the suppression of Foxo3 and TRIM31, two important tumor suppressors. In support of this, our in vivo experiments using mouse xenograft models showed that inhibiting miR-551b significantly increased the susceptibility of OVCa cells to cisplatin and prolonged the survival of the host mice. In conclusion, our study suggested miR-551b as a potential biomarker for OVCa stem cells and explored its functional mechanism, providing a potential therapeutic target for future drug development.
卵巢癌(OVCa)干细胞与肿瘤生长、转移及复发相关,而这些正是导致大多数OVCa相关死亡的驱动因素。这一亚群癌细胞的特征为不受控制的增殖、高侵袭性以及对当前铂类疗法的耐药性。因此,靶向OVCa癌干细胞已成为近期治疗研发的重点。然而,由于缺乏敏感且特异的标志物,癌干细胞的分离与纯化颇具挑战性。在本研究中,我们通过定量PCR阵列证明,miR-551b在OVCa干细胞中上调,且与该恶性肿瘤的病理分级相关。体外实验表明,miR-551b促进了OVCa细胞和癌干细胞的增殖、侵袭及化疗耐药性。进一步分析提示,miR-551b通过抑制两个重要的肿瘤抑制因子Foxo3和TRIM31发挥作用。与此相符的是,我们使用小鼠异种移植模型的体内实验表明,抑制miR-551b可显著增加OVCa细胞对顺铂的敏感性,并延长宿主小鼠的生存期。总之,我们的研究表明miR-551b是OVCa干细胞的潜在生物标志物,并探究了其功能机制,为未来药物研发提供了潜在的治疗靶点。